A pill for diabetes? new oral drug aims to rival injections

NCT ID NCT07755150

Not yet recruiting Disease control Sponsor: Chendu DIAO Pharmaceutical Group CO., LTD. Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This phase II trial is testing whether an experimental oral medication, DA-302168S, can help people with type 2 diabetes control their blood sugar. The study will compare the drug against a placebo in about 272 adults who are already taking metformin. Researchers will measure changes in HbA1c, a key blood sugar marker, along with weight and safety, to see if the pill is effective and to guide future larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DA-302168S, an experimental oral GLP-1 receptor agonist tablet
What this could lead to: If successful, this could lead to a convenient once-daily pill for type 2 diabetes that improves blood sugar control and may aid weight loss.
What could go wrong: This is an early phase II trial, so the drug may not prove effective or safe. Possible side effects include gastrointestinal issues common to GLP-1 drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Peking University People's Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.